Metabolic problems lead to numerous failures during clinical trials, and much effort is now
devoted in developing in silico models predicting metabolic stability and metabolites. Such …

Metabolic problems lead to numerous failures during clinical trials, and much effort is now
devoted to developing in silico models predicting metabolic stability and metabolites. Such …

Genetic variations in drug-metabolizing enzymes have been reported to influence
pharmacokinetics, drug dosage and other aspects that affect therapeutic outcomes. Most …

Purpose To predict and determine whether the protease inhibitors (PIs) nelfinavir,
amprenavir, atazanavir, ritonavir, and saquinavir could serve as metabolic inhibitors of the …

Members of the carboxylesterase 2 (Ces2/CES2) family have been studied intensively with
respect to their hydrolytic function on (pro) drugs, whereas their physiological role in lipid …

The human carboxylesterase 1 (CES1), responsible for the biotransformation of many
diverse therapeutic agents, may contribute to the occurrence of adverse drug reactions and …

A recombinant carboxylesterase, cloned from Pseudomonas putida and designated as
rPPE, is capable of catalyzing the bioresolution of racemic 2-acetoxy-2-(2′-chlorophenyl) …

Abstract Carboxylesterase 1 (CES1) is a primary human hepatic hydrolase involved in
hydrolytic biotransformation of numerous medications. Considerable interindividual …

Human carboxylesterase 1 (hCE-1, CES1A1, HU1) and carboxylesterase 2 (hCE-2, hiCE,
HU3) are a serine esterase involved in both drug metabolism and activation. Although both …

Abstract Human Carboxylesterase 2A (hCES2A), one of the most important serine
hydrolases, plays crucial roles in the hydrolysis and the metabolic activation of a wide range …